Skip to content
All Podcasts – Lifestyle
Author:
Dianthus Therapeutics, Inc.
Dianthus Therapeutics to Participate in Two Investor Conferences
May 26, 2026
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
May 5, 2026
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 6, 2026
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 12, 2026
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
March 9, 2026
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results
March 9, 2026
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 5, 2026
←
Previous Page
1
2